SCHEMBL4292676

SCHEMBL4292676

CC(=O)Nc1cccc(Nc2nccc(Oc3ccc4[nH]ccc4c3)n2)c1

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KDR P35968 17/20 0.51
AURKA O14965 1/20 0.47
AURKB Q96GD4 1/20 0.47
FLT1 P17948 3/20 0.47
RET P07949 2/20 0.47
PDGFRA P16234 1/20 0.46
FGFR1 P11362 1/20 0.46
FLT4 P35916 1/20 0.46
FLT3 P36888 1/20 0.46
MERTK Q12866 1/20 0.46
NTRK2 Q16620 1/20 0.46
SYK P43405 1/20 0.46
PLK1 P53350 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4287689 0.85 KDR (0.50) KDRFLT1RETFGFR1FLT4
SCHEMBL4284781 0.85 KDR (0.61) KDRFLT1RETPDGFRAFGFR1
SCHEMBL4291808 0.85 KDR (0.51) KDRAURKASYK
SCHEMBL4281016 0.83 KDR (0.54) KDRFLT1RETFGFR1FLT4
SCHEMBL4279286 0.83 KDR (0.49) KDRFLT1FGFR1FLT4FLT3
SCHEMBL4283784 0.83 KDR (0.49) KDRFLT1RETPDGFRAFGFR1
SCHEMBL4288245 0.83 CDK5 (0.49) KDRFLT1RETFGFR1FLT4
SCHEMBL4290886 0.83 KDR (0.49) KDRFLT1RETFGFR1FLT4
SCHEMBL4279265 0.81 SYK (0.46) KDRFLT1RETPDGFRAFGFR1
SCHEMBL4287622 0.79 SYK (0.48) KDRFLT1FGFR1FLT4FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US claimed
EP-1934200-A1 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2008-06-25 EP claimed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO claimed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
EP-1934200-A1 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2008-06-25 EP disclosed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO disclosed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149467-A1 Tyrosine Kinase Inhibitors ABL1, MET, ERBB2 KDR 165/4885AURKA 521/4885AURKB 305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.